www.nbcnews.com Open in urlscan Pro
2a02:26f0:3100:795::2506  Public Scan

Form analysis
2 forms found in the DOM

GET https://www.nbcnews.com/search

<form action="https://www.nbcnews.com/search" method="GET" class="search-form js-search-form"><label class="search-label" for="q" id="search_label">Search</label>
  <div class="search-inner"><input type="search" class="search-input js-search-input" aria-labelledby="search_label" id="q" name="q" placeholder="Search NBC News" tabindex="-1"><button class="search-button" tabindex="-1"><span
        class="search-button-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-labelledby="search_title">
          <title class="search_title">Search</title>
          <path fill-rule="evenodd" d="M13.773 11.649L20 17.876 17.876 20l-6.227-6.227a7.508 7.508 0 112.124-2.124zm-6.265.364a4.505 4.505 0 100-9.01 4.505 4.505 0 000 9.01z"></path>
        </svg></span></button></div>
</form>

GET https://www.nbcnews.com/search

<form action="https://www.nbcnews.com/search" method="GET" class="search-form js-search-form"><label class="search-label" for="q" id="search_label">Search</label>
  <div class="search-inner"><input type="search" class="search-input js-search-input" aria-labelledby="search_label" id="q" name="q" placeholder="Search NBC News"><button class="search-button"><span class="search-button-icon"><svg
          xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-labelledby="search_title">
          <title class="search_title">Search</title>
          <path fill-rule="evenodd" d="M13.773 11.649L20 17.876 17.876 20l-6.227-6.227a7.508 7.508 0 112.124-2.124zm-6.265.364a4.505 4.505 0 100-9.01 4.505 4.505 0 000 9.01z"></path>
        </svg></span></button></div>
</form>

Text Content

IE 11 is not supported. For an optimal experience visit our site on another
browser.
SKIP TO CONTENT
NBC News Logo
Sponsored By

 * Hunter Biden trial
 * D-Day Anniversary
 * Politics
 * U.S. News
 * World
 * Business
 * NBC News Tipline
 * Sports
 * Shopping
 * Health
 * Culture & trends

Watch live



Male birth control gel is safe and effective, new trial findings show

 * Share & Save —
 * 
 * 
 * 
 * 
 * 


My NewsManage ProfileEmail PreferencesSign Out
Search
Search

Profile

 My NewsSign Out
 Sign InCreate your free profile

Sections

 * U.S. News
 * Politics
 * World
 * Local
 * Business
 * Sports
 * Paris 2024 Olympics
 * Investigations
 * Culture & Trends
 * Health
 * Science
 * Tech & Media
 * Weather
 * Video Features
 * Photos
 * NBC Select
 * Decision 2024
 * NBC Asian America
 * NBC BLK
 * NBC Latino
 * NBC OUT

tv

 * Today
 * Nightly News
 * MSNBC
 * Meet the Press
 * Dateline

Featured

 * NBC News Now
 * Nightly Films
 * Stay Tuned
 * Special Features
 * Newsletters
 * Podcasts
 * Listen Now

More From NBC

 * CNBC
 * NBC.COM
 * NBCU Academy
 * Peacock
 * NEXT STEPS FOR VETS
 * NBC News Site Map
 * Help

Follow NBC News

 * 
 * 
 * 


NEWS ALERTS

There are no new alerts at this time

Search
Search
 * Facebook
 * Twitter
 * Email
 * SMS
 * Print
 * Whatsapp
 * Reddit
 * Pocket
 * Flipboard
 * Pinterest
 * Linkedin


 * Latest Stories
 * Hunter Biden trial
 * D-Day Anniversary
 * Politics
 * U.S. News
 * World
 * Business
 * NBC News Tipline
 * Sports
 * Shopping
 * Health
 * Culture & trends




Men's Health


MALE BIRTH CONTROL GEL IS SAFE AND EFFECTIVE, NEW TRIAL FINDINGS SHOW

After decades of attempts to develop new birth control medications for men,
scientists are more hopeful than ever. With new abortion restrictions, demand is
growing, experts say.

Surveys have found that men are willing to use new types of birth control
medication.Leila Register / NBC News; Getty Images
 * 
 * 
 * 
 * 
 * 
 * 
 * Print
 * 

June 2, 2024, 6:01 PM GMT+2
By Caroline Hopkins

Every morning for a year and a half, Logan Whitehead, 24, rubbed a clear gel on
his shoulders, waited for it to dry, then went about his day as usual.

“It was basically like a hand sanitizer solution,” said Whitehead, who lives in
Torrance, California. “Smelled like hand sanitizer, looked like hand sanitizer.”




The gel wasn’t hand sanitizer, though. It was a hormonal solution meant to block
Whitehead’s sperm production. The gel was male birth control.

Until this past winter when his participation concluded, Whitehead was a
volunteer in a phase 2 trial for the gel. The product — which contains
testosterone and a synthetic hormone called Nestorone that reduces sperm
production — is the most advanced among a crop of novel birth control options
for men.

If the Food and Drug Administration approves the gel, Whitehead said he would
definitely keep using it, especially after watching his partner struggle with
available female birth control options.

“The gel was such an easy process,” he said. “It was basically like taking the
pill for the day.”



Whitehead said he didn’t notice side effects using the gel beyond some upper
back acne and possibly a bit of weight gain, although that could have been
linked to a new sedentary job.


HORMONAL GEL TRIAL SHOWS PROMISE

On Sunday, at the Endocrine Society’s conference in Boston, researchers with the
National Institutes of Health’s Contraceptive Development Program presented
encouraging phase 2 trial results on the hormonal gel.

The trial involved 222 men, ages 18 to 50, who applied 5 milliliters of the gel
(about a teaspoon) to each of their shoulder blades once per day.

The second part of the two-part trial is still underway. Initial findings showed
that the contraceptive worked faster than expected, according to Diana Blithe,
chief of NIH’s Contraceptive Development Program.

After 12 weeks of applying the gel every day, 86% of trial participants achieved
sperm suppression, meaning they had only up to 1 million sperm per milliliter of
semen, the amount the researchers deemed effective for contraception. On
average, the timing for effective contraception was eight weeks.

In comparison, normal sperm counts without contraception can range from 15
million to 200 million per milliliter.



The faster-than-expected timing to suppress sperm is an encouraging sign,
especially since past attempts have taken longer to reach these sperm levels,
Blithe said in a news release about the new data.

Prior efforts using testosterone alone have required higher doses of the
hormone, which can cause side effects. Because the gel includes both
testosterone and Nestorone, it acts more quickly and requires less testosterone,
she said.

Nestorone is a type of synthetic hormone called a progestin that’s already used
in the vaginal ring contraceptive. Combining Nestorone and testosterone in the
new gel is meant to keep men from producing sperm without affecting their sex
drive or causing other side effects.

So far, the men in the gel clinical trial have shown low enough blood levels of
testosterone to maintain their normal sexual function.

Researchers are now tracking how well the gel works to prevent pregnancy.
Because of pregnancy risk, male participants are required to be in committed,
monogamous relationships, and need consent from their female partners too. The
couple must agree to use the gel as their only birth control and to have sex at
least once a month for a year. Throughout the study, men have their sperm counts
tested periodically, which is a good predictor of fertility. If the sperm counts
remain low, the chances of pregnancy are slim.

After decades of early-stage attempts and failures, there are no federally
approved male birth control drugs. Only a handful have even advanced into human
trials.



It’s not because the approaches haven’t shown potential, researchers say, but
because there hasn’t been enough funding or financial investment to complete
expensive advanced human trials.

“We’ve been pushing for hormonal male contraceptives for 50 years, but there
isn’t enough money available to really drive something through a very large
phase 3 trial,” said Daniel Johnston, chief of the National Institute of Child
Health and Human Development’s Contraception Research Branch.

If one male birth control drug gains approval from the FDA, pharmaceutical
companies and industry investors would put more resources into other medications
or products, Johnston believes.

“We’ve been chasing this for a long time,” Johnston said. “I hope we’re entering
new territory.”


NONHORMONAL OPTIONS IN DEVELOPMENT

Also on Sunday, YourChoice Therapeutics said a very small trial in the U.K. —
just 16 men — showed that its nonhormonal pill, YCT-529, was safe and free of
side effects. The San Francisco company’s nonhormonal pill works by blocking the
vitamin A receptor important for male fertility.


RECOMMENDED

Business News


BUSINESS NEWSFDA REVERSES MARKETING BAN ON JUUL E-CIGARETTES

Heart Health


HEART HEALTHCOMMON SUGAR SUBSTITUTE LINKED TO INCREASED RISK OF HEART ATTACK AND
STROKE

YourChoice is planning a larger trial, according to CEO Akash Bakshi.



“We’re excited to see what happens next,” Bakshi said.

Separately, a Charlottesville, Virginia, medical device company, Contraline, is
developing a nonhormonal male birth control method that involves injecting a gel
into the vas deferens, the tubes that transport sperm from the testicles.

Injecting the gel, called ADAM, involves a single, 15-minute procedure, said
Kevin Eisenfrats, Contraline’s CEO and co-founder. Then, the gel is meant to
stay in place for years. Contraline compares the long-acting reversible
contraceptive to an intrauterine device (IUD) for women.

Contraline has been testing ADAM in an early clinical trial in Australia. In
January, the company reported that among 25 clinical trial participants, the
approach resulted in a 99.8% to 100% reduction in the number of motile sperm
within 30 days of the procedure, Eisenfrats said.

“It’s honestly very similar to the experience patients have after a vasectomy,”
he said. “Some of these patients had light bruising and swelling, which go away
on their own.”

Contraline hopes to start testing ADAM in the U.S. in 2025.



Because Contraline is developing ADAM as a medical device and not a drug, it may
be able to go through a speedier clinical trial and regulatory process than
contraceptive drugs like the hormonal gel, experts suggest.

If it goes according to plan — which can be rare for novel products with no
precedent — Eisenfrats said he’s aiming for an FDA approval in 2027.

Another company called Next Life Sciences is developing a similar method. Next
Life’s approach, called Plan A, or Vasalgel, also involves blocking the vas
deferens with a gel-like injection. Next Life is based in Flagstaff, Arizona.
Next Life hasn’t started testing Plan A in people yet, although the company did
test its method of injecting the gel in Canadian volunteers this past year.


DEMAND FOR NEW CONTRACEPTION IS GROWING

U.S. and global surveys have found that men are willing to use contraception,
said gynecologist Dr. Brian Nguyen, one of the investigators on the gel clinical
trials.

“By and large, they always say they’d be interested,” said Nguyen, an associate
professor of obstetrics and gynecology at the University of Southern California.

According to one 2023 survey published in the journal Contraception,
three-quarters of 2,066 male respondents said they’d be willing to use new
contraceptives.



In 2019, the nonprofit Male Contraceptive Initiative estimated more than 17
million men in the U.S. want more birth control options.

Heather Vahdat, the Male Contraceptive Initiative’s executive director, said
interest in male birth control has been on the rise since the Supreme Court
overturned Roe v. Wade in 2022.

0 seconds of 4 minutes, 11 secondsVolume 90%

Press shift question mark to access a list of keyboard shortcuts
Keyboard ShortcutsEnabledDisabled
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9

Settings
OffCCEnglish
Font Color
White

Font Opacity
100%

Font Size
100%

Font Family
Arial

Character Edge
None

Background Color
Black

Background Opacity
50%

Window Color
Black

Window Opacity
0%

Reset
WhiteBlackRedGreenBlueYellowMagentaCyan
100%75%50%25%
200%175%150%125%100%75%50%
ArialCourierGeorgiaImpactLucida ConsoleTahomaTimes New RomanTrebuchet MSVerdana
NoneRaisedDepressedUniformDrop Shadow
WhiteBlackRedGreenBlueYellowMagentaCyan
100%75%50%25%0%
WhiteBlackRedGreenBlueYellowMagentaCyan
100%75%50%25%0%
Auto270p (289 kbps)1080p (4589 kbps)720p (3450 kbps)540p (1751 kbps)360p (956
kbps)270p (511 kbps)270p (289 kbps)
Live
00:00
04:11
04:11






 

Permanent contraception in young people on the rise after abortion restrictions
04:12

Recent research from the University of Pittsburgh School of Public Health found
that the number of young women and men choosing permanent birth control such as
vasectomy and tubal ligation increased sharply after the court’s decision and
has continued to rise.



A separate study conducted in part by the Male Contraceptive Initiative, showed
that before the abortion ruling, 78% of men in the U.S. said they were
interested in trying new birth control methods. Afterward, it climbed to 82%.

“The demand has always been there, but there’s a greater intensity now,” Vahdat
said. “We get emails daily from people asking where they can sign up for
clinical trials.”

Unlike a vasectomy, each of the new contraceptive approaches is meant to be
reversible, so men can stop using them and regain their ability to have
children.



“Vasectomies are a great solution for men who are done having kids,” Eisenfrats
said. But reversing the procedure — which involves reattaching the vas deferens
in a three-hour microsurgery — can be extremely challenging and doesn’t always
work, he said.

While condoms can be highly effective against pregnancy or sexually transmitted
infections when used perfectly, perfect use is hard to achieve. And condoms
generally aren’t the preferred contraceptive in long-term relationships,
YourChoice’s Bakshi said. 


WHY IS MALE BIRTH CONTROL TAKING SO LONG?

The new trial results are encouraging to Vahdat. But she knows that it’s not
enough to show a birth control method is safe and effective. The product needs
substantial buy-in from investors, too.

“We have this classic line, ‘Male contraceptives have been 10 years away for 50
years,’” Vahdat said.

The reason, she believes, boils down to lack of funding.

After NIH research grants, the Male Contraceptive Initiative is the
second-biggest funder of male contraceptive research in the world, according to
Vahdat.



“That’s super exciting, except when you consider we only grant about $1.5
million a year,” she said.

On average, the Congressional Budget Office ballparks $1 billion to $2 billion
as the amount needed to take a drug through clinical trials and onto the market.

Right now, there’s just not enough money to take any of these male birth control
approaches through the FDA review process, USC’s Nguyen said.

The hormonal gel is the most advanced in clinical trials, but it still hasn’t
gone through a much larger, lengthy phase 3 trial. As of now — in part due to
funding uncertainties — plans to test the gel further are still up in the air.

Most academic researchers or small biotech companies developing new drugs rely
on drugmakers with deep pockets to fund advanced trials. In exchange, these
bigger companies usually expect a cut of profit once the drugs make it to
market.

The studies so far have been funded by NIH and the independent nonprofit
Lundquist Institute in Torrance, California.



As of now, Nguyen said, there’s no major pharmaceutical company stepping in to
fund the male contraceptive gel’s next-stage trials.

“There has to be an industry partner,” he said.

Nguyen thinks the challenge is that despite evidence that men want options, many
couples still depend on female birth control.

“But that doesn’t mean they are satisfied with them and wouldn’t appreciate a
male method.” Nguyen said.

“People always ask, ‘How long will it be until we see this product on the
market?’” Nguyen said. “Most people will say five to 10 years, but I disagree.”

However, the chance of any of these male contraceptives — the gel, the physical
blockers, the pills and whichever new methods crop up next — making it to market
depends on whether investors with deep pockets recognize the demand is really
there, Vahdat said.



To reach this point, she believes, the conversation has to shift away from
viewing male contraception and female contraception as mutually exclusive
landscapes with two separate populations demanding them.

“I think of male contraception as women’s health,” she said. “You’re still
preventing unintended pregnancy.”

Caroline Hopkins

NBC News contributor Caroline Hopkins is a health and science journalist who
covers cancer treatment for Precision Oncology News. She is a graduate of the
Columbia University Graduate School of Journalism.  



 * About
 * Contact
 * Help
 * Careers
 * Ad Choices
 * Privacy Policy
 * Cookie Notice
 * CA Notice
 * Terms of Service (Updated JULY 7, 2023)
 * NBC News Sitemap
 * Closed Captioning
 * Advertise
 * Select Shopping
 * Select Personal Finance

© 2024 NBC UNIVERSAL

NBC News LogoMSNBC LogoToday Logo



We and our partners use cookies on this site to improve our service, perform
analytics, personalize advertising, measure advertising performance, and
remember website preferences. By using the site, you consent to these cookies.
For more information on cookies including how to manage your consent visit our
Cookie Policy.
Continue



COOKIE NOTICE

This Cookie Notice (“Notice”) explains how NBCUniversal and its affiliates
(“NBCUniversal” or “we”), along with our partners, including advertisers and
vendors, use cookies and similar tracking technologies when you use our
websites, applications, such as games, interactive TV, voice-activated
assistants, and other services that link to this policy, as well as connected
devices, including those used in our theme parks (“Services”). This Notice
provides more information about these technologies, your choices, and is part of
the NBCUniversal Privacy Policy available here. You should read the Privacy
Policy and this Notice for a full picture of NBCUniversal’s use of your
information.

WHAT ARE COOKIES AND HOW ARE THEY USED?

Like many companies, we use cookies (small text files placed on your computer or
device) and other tracking technologies on the Services (referred to together
from this point forward as “Cookies”, unless otherwise stated), including HTTP
cookies, HTML5 and Flash local storage/flash cookies, web beacons/GIFs, embedded
scripts, ETags/cache browsers, and software development kits.

First-party Cookies

First-party Cookies are placed by us (including through the use of third-party
service providers) and are used to allow you to use the Services and their
features and to assist in analytics activities.

Third-party Cookies

Certain third parties may place their Cookies on your device and use them to
recognize your device when you visit the Services and when you visit other
websites or online services. These third parties collect and use this
information pursuant to their own privacy policies. Third-party Cookies enable
certain features or functionalities, and advertising, to be provided on the
Services.

Types of Cookies

The Services use the following types of first and third-party Cookies for these
purposes:

Strictly Necessary Cookies: These Cookies are required for Service
functionality, including for system administration, security and fraud
prevention, and to enable any purchasing capabilities. You can set your browser
to block these Cookies, but some parts of the site may not function properly.

Information Storage and Access: These Cookies allow us and our partners to store
and access information on the device, such as device identifiers.

Measurement and Analytics: These Cookies collect data regarding your usage of
and performance of the Services, apply market research to generate audiences,
and measure the delivery and effectiveness of content and advertising. We and
our third-party vendors use these Cookies to perform analytics, so we can
improve the content and user experience, develop new products and services, and
for statistical purposes. They are also used to recognize you and provide
further insights across platforms and devices for the above purposes.

Personalization Cookies: These Cookies enable us to provide certain features,
such as determining if you are a first-time visitor, capping message frequency,
remembering choices you have made (e.g., your language preferences, time zone),
and assist you with logging in after registration (including across platforms
and devices). These Cookies also allow your device to receive and send
information, so you can see and interact with ads and content.

Content Selection and Delivery Cookies: Data collected under this category can
also be used to select and deliver personalized content, such as news articles
and videos.

Ad Selection and Delivery Cookies: These Cookies are used to collect data about
your browsing habits, your use of the Services, your preferences, and your
interaction with advertisements across platforms and devices for the purpose of
delivering interest-based advertising content on the Services and on third-party
sites. Third-party sites and services also use interest-based Advertising
Cookies to deliver content, including advertisements relevant to your interests
on the Services and third-party services. If you reject these Cookies, you may
see contextual advertising that may be less relevant to you.

Social Media Cookies: These Cookies are set by social media platforms on the
Services to enable you to share content with your friends and networks. Social
media platforms have the ability to track your online activity outside of the
Services. This may impact the content and messages you see on other services you
visit.

We and third parties may associate Measurement And Analytics Cookies,
Personalization Cookies, Content Selection, Delivery Cookies, and Reporting, Ad
Selection, Delivery and Reporting Cookies, and Social Media Cookies with other
information we have about you.

COOKIE MANAGEMENT

Depending on where you live, you may be able to adjust your Cookie preferences
at any time via the “Cookie Settings” link in the footer of relevant websites.
You can also use the methods described below to manage Cookies. You must take
such steps on each browser or device that you use. If you replace, change or
upgrade your browser or device, or delete your cookies, you may need to use
these opt-out tools again. As some Cookie-management solutions also rely on
Cookies, please adjust your browser Cookie settings carefully, following the
relevant instructions below.

Browser Controls: You may be able to disable and manage some Cookies through
your browser settings. If you use multiple browsers on the same device, you will
need to manage your settings for each browser. Please click on any of the below
browser links for instructions:

Google Chrome
Apple Safari
Mozila Firefox
Microsoft Internet Explorer

If the browser you use is not listed above, please refer to your browser’s help
menu for information on how to manage Cookies. Please be aware that disabling
cookies will not disable other analytics tools we may use to collect information
about you or your use of our Services.

Analytics Provider Opt-Outs: To disable analytics Cookies you can use the
browser controls discussed above or, for some of our providers, you can use
their individual opt-out mechanisms:

Google’s Privacy Policy and Google Analytics Opt-Out
Omniture’s Privacy Policy and Omniture’s Opt-Out
Mixpanel’s Privacy Policy and Mixpanel’s Opt-Out

The above are examples of our analytics providers and this is not an exhaustive
list. We are not responsible for the effectiveness of any other providers’
opt-out mechanisms.

Flash Local Storage: These cookies are also known as local shared objects and
may be used to store your preferences or display content by us, advertisers and
other third-parties. Flash cookies need to be deleted in the storage section of
your Flash Player Settings Manager.

Interest-Based Advertising: Most third-party advertisers offer a way to opt out
of their interest-based advertising. For more information or to opt out of
receiving interest-based advertising from participating third-party advertisers,
depending on your country of residence, please visit:

Digital Advertising Alliance in the US
Digital Advertising Alliance of Canada
European Interactive Digital Advertising Alliance
Australian Digital Advertising Alliance

You can also opt out of some of the advertising providers we use by visiting
their opt-out pages:

Google’s Privacy Policy and Google Analytics Opt-Out Page
Facebook Privacy Policy and Facebook’s Opt-Out Page
Twitter Privacy Policy and Twitter’s Opt-Out Page
Liveramp’s Privacy Policy and Liveramp Opt-Out Page

These are examples of our advertising providers and this is not an exhaustive
list. In addition, we are not responsible for the effectiveness of any of these
providers’ opt-out mechanisms.

After you opt out, you will still see advertisements, but they may not be as
relevant to you.

Mobile Settings: You may manage the collection of information for interest-based
advertising purposes in mobile apps via the device’s settings, including
managing the collection of location data. To opt out of mobile ad tracking from
Nielsen or other third parties, you can do so by selecting the “Limit Ad
Tracking” (for iOS devices) or “Opt out of Ads Personalization” (for Android
devices) options in your device settings.

Connected Devices: For connected devices, such as smart TVs or streaming
devices, you should review the device’s settings and select the option that
allows you to disable automatic content recognition or ad tracking. Typically,
to opt out, such devices require you to select options like “limit ad tracking”
or to disable options such as “interest-based advertising,” “interactive TV,” or
“smart interactivity”. These settings vary by device type.

Cross-Device Tracking: If you would like to opt out of our browser-based
cross-device tracking for advertising purposes, you may do so by using the
various methods described above. You must opt out separately on each device and
each browser that you use. For more information about cross-device matching,
please visit the Network Advertising Initiative or the Digital Advertising
Alliance. If you opt out of cross-device tracking for advertising purposes, we
may still conduct cross-device tracking for other purposes, such as analytics.

Consequences of Deactivation of Cookies: If you disable or remove Cookies, some
parts of the Services may not function properly. Information may still be
collected and used for other purposes, such as research, online services
analytics or internal operations, and to remember your opt-out preferences.



CONTACT US

For inquiries about this Cookies Notice, please contact us at Privacy@nbcuni.com
or Chief Privacy Officer, NBCUniversal Legal Department, 30 Rockefeller Plaza,
New York, NY 10112, US.

For inquiries from users who reside in the European Economic Area, the United
Kingdom or Switzerland, please contact us at Privacy@nbcuni.com or Privacy,
Legal Department, Central Saint Giles, St Giles High Street, London, WC2H 8NU,
UK

CHANGES TO THIS NOTICE

This Notice may be revised occasionally and in accordance with legal
requirements. Please revisit this Cookie Notice regularly to stay informed about
our and our analytic and advertising partners’ use of Cookies.

STRICTLY NECESSARY COOKIES

Always Active

These Cookies are required for Service functionality, including security and
fraud prevention, and to enable any purchasing capabilities. You can set your
browser to block these Cookies, but some parts of the site may not function
properly.

Back Button


COOKIE LIST



Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Close